Isomorphic Labs signals pivot from research to execution with appointment of Max Jaderberg as President

Isomorphic Labs, the AI-driven drug discovery company spun out of DeepMind in 2021, has appointed Max JaderbergDealroom has a profile for this one. Try Dealroom → as its new president, starting in January 2026, marking a significant moment in the firm’s evolution. Jaderberg, who has served as the company’s Chief AI Officer, is expected to steer the organisation as it expands its scientific and commercial ambition.

Jaderberg brings a long-standing background in advanced machine learning. Before joining Isomorphic Labs, he led DeepMind’s Open-Ended Learning team and contributed to breakthroughs in reinforcement learning and generative modelling. Earlier in his career, he co-founded Vision FactoryDealroom has a profile for this one. Try Dealroom →, a deep-learning startup later acquired by Google, giving him experience at the intersection of research, product development and applied AI at scale.

His appointment underscores the company’s intention to embed AI research even more deeply into its drug discovery efforts. Isomorphic Labs has sought to reimagine the early stages of medicine development by integrating computational modelling, molecular simulation and generative design. The company builds on foundations laid by the AlphaFold protein-folding work but aims to extend those capabilities toward the modelling of molecular interactions, the design of novel therapeutics and the acceleration of candidate selection.

Under Jaderberg’s leadership, the company is positioning itself for a phase of expansion, aiming to translate its scientific advances into drug discovery programmes with partners across the pharmaceutical sector. The move also signals a strengthening of the firm’s interdisciplinary approach, combining machine learning with structural biology, chemistry and pharmacology.

Looking ahead, Isomorphic Labs appears set to deepen its focus on “digital biology” — using AI systems not only to understand biological structures but to design new molecules and predict their behaviour with increasing accuracy. With Jaderberg at the helm, the company’s next chapter will centre on scaling these technologies and demonstrating their potential impact on the development of new medicines.

Source:
Isomorphic Labs

J.V.